Consider how changes in the pharmacokinetic and pharmacodynamic processes might impact the patient’s .Think about how you might improve the patient’s drug therapy plan based on the pharmacokinetic and pharmacodynamic changes. Reflect on whether you would modify the current drug treatment or provide an alternative treatment option for the patient.By Day 7 of Week 2Write a 2- to 3-page paper that addresses the following:
Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.Describe how changes in the processes might impact the patient’s recommended drug therapy. Be specific and provide examples.Explain how you might improve the patient’s drug therapy plan and explain why you would make these recommended improvements.For Week 2, you will examine how patient factors may influence pharmacokinetic and pharmacodynamic processes of pharmacotherapeutics used in the treatment of cardiovascular disorders. You also explore ways to improve drug therapy plans for cardiovascular disorders based on patient factors and overall health needs.
When writing your Week 2 Assignment, consider the following scenario:
Patient HM has a history of atrial fibrillation and a transient ischemic attack (TIA). The patient has been diagnosed with type 2 diabetes, hypertension, hyperlipidemia and ischemic heart disease. Drugs currently prescribed include the following:
Warfarin 5 mg daily MWF and 2.5 mg daily T, TH, Sat, SunAspirin 81 mg dailyMetformin 1000 mg po bidGlyburide 10 mg bidAtenolol 100 mg po dailyMotrin 200 mg 1–3 tablets every 6 hours as needed for painEvidence-based clinical practice guidelines are fundamental to clinical practice, as they assist providers with clinical decision making. I have attached some applicable guidelines below for your reference.
Have a great week!
2017 ACC-AHA Guideline Mgmt HTN in Adults.pdf
2018 AHA-ACC Guideline on Mgmt Blood Cholesterol.pdf
2017 ACC-AHA-HFSA Guideline Mgmt HF.pdf
ASH 2018 Guidelines Mgmt of VTE_Optimal Anticoag.pdf
2019 AHA-ACC-HRS Guideline for Mgmt A Fib.pdf
2017 AHA-ACC Guideline Mgmt Valvular Heart Disease.pdf
Place Your Order Here